Andere talen Satellos Bioscience Inc.

Aandelen

MSCL

CA80401L3083

Beurs gesloten - Toronto S.E. Andere beurzen 21:53:03 28-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,52 ^CAD	-3,70%		-11,86%	+20,93%

28/05	Satellos Bioscience Inc. kondigt de vorming van een klinische adviesraad aan	CI
14/05	Satellos Bioscience Inc. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Satellos Announces Presentation at Parent Project Muscular Dystrophy 30th Annual Conference	28/06
Satellos Bioscience Inc. Brief: Adds Trial will evaluate the safety and pharmacokinetic properties of SAT-3247 in healthy human volunteers	27/06
Satellos Bioscience Inc. Brief: Co Says intends to submit a regulatory package in July to initiate a first-in-human Phase 1 clinical trial, in Q3 2024	27/06
Satellos Bioscience Inc. Brief: Says CEO Frank Gleeson Participating at Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference	27/06
Satellos Announces Presentation at Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference	27/06
Satellos Bioscience Forms Advisory Board to Advance SAT-3247 in Duchenne Muscular Dystrophy Treatment	28/05
Satellos Bioscience Inc. Brief: Announcing Formation of Clinical Advisory Board to Support Advancing SAT-3247 in Clinical Trial Development for Duchenne Muscular Dystrophy	28/05
Satellos Announces Formation of Clinical Advisory Board to Support Advancing SAT-3247 in Clinical Trial Development for Duchenne Muscular Dystrophy	28/05
Satellos Bioscience Inc. Announces Formation of Clinical Advisory Board	28/05
Satellos Bioscience Inc. Opens the Market	15/05
Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders	14/05
Satellos Bioscience: Q1 Earnings Snapshot	14/05
Satellos Bioscience Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Satellos Bioscience Q1 Loss Widens Due To Higher Expenses; But Says "On track" to initiate Phase 1 First-in-human Clinical Trials Mid-2024	14/05
Satellos Bioscience Announces Q1 2024 Financial Results and Operational Highlights	14/05
Satellos to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	08/04
Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Satellos Bioscience: Q4 Earnings Snapshot	27/03
Satellos Bioscience Announces FY 2023 Results	27/03
Satellos Bioscience Announces 2023 Year End Financial Results and Operational Highlights	27/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Satellos Bioscience Inc.

Aandelen

MSCL

CA80401L3083

Andere talen

Filters